Publicaciones en las que colabora con José Luis Prada Pardal (8)

2017

  1. Simplification to dual therapy (atazanavir/ritonavir1lamivudine) versus standard triple therapy [atazanavir/ritonavir1two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study)

    Journal of Antimicrobial Chemotherapy, Vol. 72, Núm. 1, pp. 246-253

2015

  1. Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial

    The Lancet Infectious Diseases, Vol. 15, Núm. 7, pp. 775-784

2008

  1. Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of hiv type 1 infection: Final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903

    Clinical Infectious Diseases, Vol. 47, Núm. 8, pp. 1083-1092

  2. Low rate of adverse hepatic events associated with fosamprenavir/ritonavir-based antiretroviral regimens

    HIV Clinical Trials, Vol. 9, Núm. 5, pp. 309-313

2006

  1. Impacto de los factores demográficos y psicosociales en la no adherencia a los fármacos antirretrovirales

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 24, Núm. 6, pp. 373-378

2005

  1. Clinical status, adherence to HAART and quality of life in HIV-infected patients receiving antiretroviral treatment

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 23, Núm. 10, pp. 581-585

  2. Health-related quality of life of patients with HIV: Impact of sociodemographic, clinical and psychosocial factors

    Quality of Life Research, Vol. 14, Núm. 5, pp. 1301-1310

  3. Impacto del apoyo social y la morbilidad psíquica en la calidad de vida en pacientes tratados con antirretrovirales

    Psicothema, Vol. 17, Núm. 2, pp. 245-249